Tra storia della matematica e macchine matematiche: l’esperienza degli studenti al museo

Increase in fetal haemoglobin from baseline to day 10 is a biomarker for response to decitabine in AML : Results of the AML21 randomized phase III trial of the EORTC Leukemia Group, Gruppo Italiano Malattie Ematologiche dell'Adulto ( GIMEMA) and German MDS Study Group

: Lack of response or delayed response to therapy are major challenges in the use of DNA-hypomethylating agents (HMA) in patients with acute myeloid leukaemia (AML). Fetal haemoglobin (HbF) is a potential biomarker for response to HMA treatment but has only been studied in small single-centre studies. We investigated the association between HbF and treatment outcome in the randomized phase 3 European Organisation for Research and Treatment of Cancer (EORTC)-1301 trial AML21, which includ...

Prognostic Impact of FLT3 ‐ ITD Microclones in AML : An EHA AML ‐Specialized Working Group Study

: The 2022 ELN recommendations reclassified fms-like tyrosine kinase-3 (FLT3)-ITD mutated acute myeloid leukemia (AML) as intermediate-risk, irrespective of allelic ratio (AR), and designated capillary electrophoresis (CE) as the preferred detection method. However, CE requires substantial expertise, particularly to identify FLT3-ITD microclones (FLT3-ITDm; AR < 0.05), whose clinical significance remains uncertain. Herein, we investigated diagnostic aspects and the prognostic impact of FLT...

Clinical Outcomes of Younger Adults With Philadelphia-Negative Acute Lymphoblastic Leukemia, Treated With A Pediatric-Like Regimen Based on the GIMEMA LAL1308 Protocol. A Campus ALL Study

Introduction: While pediatric-based protocols have significantly improved survival rates in adolescents and young adult (AYA) patients with Philadelphia-negative acute lymphoblastic leukemia (Ph- ALL), limited information is available on the applicability of pediatric-like chemotherapy in real life outside of clinical trials. Methods: We retrospectively collected clinical data from 36 AYA patients (median age 21 years, range 18-38) with Ph- ALL (28) or lymphoblastic lymphoma (LL) (8) who rece...